About 306,000 results
Open links in new tab
  1. Overcoming Barriers in Sjögren Disease Care - Medscape

    3 days ago · Dr Teja Kapoor explores how cultural sensitivity and awareness can overcome barriers to timely Sjögren disease management in diverse communities.

  2. Advances in PNH From ASH 2025 - Medscape

    Dec 31, 2025 · Artificial intelligence to speed diagnosis, switching complement therapies, ravulizumab during pregnancy, and iptacopan outcomes are some of the PNH advances from ASH 2025.

  3. SABCS 2025: Translating Evidence to HR+/HER2- Care - Medscape

    4 days ago · Dr Avan Armaghani reflects on the clinical impact of SABCS 2025, highlighting oral SERDs, ctDNA monitoring, and new data on ADC sequencing.

  4. Safety Plan: A Physical Resource for a Mental Health Crisis

    4 days ago · Dr Kaitlin Sanzone discusses tips for creating a safety plan for mental health crises.

  5. The Art of a Consult - Medscape

    This transcript has been edited for clarity. Consults are a huge part of residency, and the way you call them sets the tone for collaboration. A good consult page answers three questions: Who is ...

  6. Clinical Judgment: Transitioning to Residency - Medscape

    Dr Kaitlin Sanzone discusses the transition from medical school to residency.

  7. How to Address Potential Red Flags on Applications - Medscape

    Dr Nayiri Guedikian discusses how to address potential red flags on applications.

  8. The Removal of the Black Box on HT: Will Women’s Health ... - Medscape

    6 days ago · Dr JoAnn Manson discusses why the FDA’s removal of the 'black box' warning on hormone therapy is a long-overdue victory for personalized medicine and shared …

  9. Baking Soda Skin Hacks: The Sting Isn’t Worth the Rub

    Over the past several years, skinfluencers have gathered on TikTok to tout the benefits of baking soda-based mixtures, scrubs, and overnight masks.

  10. Chronic Myeloid Leukemia Highlights From ASH 2025 - Medscape

    Dec 30, 2025 · Chronic myeloid leukemia highlights from ASH 2025 include data on nilotinib vs imatinib, asciminib in second line, somatic mutations and imatinib failure, and dasatinib with a switch to imatinib.